Media coverage about Omnicell (NASDAQ:OMCL) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Omnicell earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.7580356530801 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news articles that may have impacted Accern’s scoring:

Several equities analysts have recently weighed in on OMCL shares. Piper Jaffray Companies downgraded Omnicell from an “overweight” rating to a “neutral” rating and set a $40.00 target price on the stock. in a research report on Friday, April 21st. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $53.00 target price (up previously from $43.00) on shares of Omnicell in a research report on Tuesday, April 25th. CIBC raised their target price on Omnicell from $43.00 to $53.00 and gave the company an “outperform” rating in a research report on Wednesday, April 26th. TheStreet downgraded Omnicell from a “b-” rating to a “c+” rating in a research report on Thursday, May 4th. Finally, Zacks Investment Research downgraded Omnicell from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $49.00.

Omnicell (OMCL) traded up 2.24% during midday trading on Friday, hitting $50.10. The company had a trading volume of 227,601 shares. The stock’s market cap is $1.88 billion. The stock’s 50-day moving average price is $45.37 and its 200-day moving average price is $41.17. Omnicell has a 52-week low of $30.35 and a 52-week high of $51.98.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, July 27th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.02. Omnicell had a positive return on equity of 0.41% and a negative net margin of 1.14%. The firm had revenue of $180.90 million for the quarter, compared to analyst estimates of $174.08 million. During the same quarter in the prior year, the company earned $0.38 EPS. Omnicell’s revenue was up 4.6% on a year-over-year basis. On average, equities research analysts expect that Omnicell will post $1.31 EPS for the current fiscal year.

In related news, VP J Christopher Drew sold 11,375 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $51.16, for a total value of $581,945.00. Following the sale, the vice president now owns 139,201 shares of the company’s stock, valued at approximately $7,121,523.16. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Peter J. Kuipers sold 18,054 shares of the company’s stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $50.31, for a total value of $908,296.74. Following the completion of the sale, the vice president now directly owns 44,236 shares in the company, valued at approximately $2,225,513.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 199,823 shares of company stock worth $9,301,391. 3.77% of the stock is owned by corporate insiders.

WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at

Omnicell Company Profile

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Insider Buying and Selling by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.